{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T23:21:33Z","timestamp":1768000893132,"version":"3.49.0"},"reference-count":11,"publisher":"The Pediatric Pharmacy Association","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022]]},"abstract":"<jats:sec>\n          <jats:title>OBJECTIVE<\/jats:title>\n          <jats:p>To evaluate the association between methylnaltrexone and urine output (UOP) in critically ill children with opioid-associated urinary retention.<\/jats:p>\n        <\/jats:sec>\n        <jats:sec>\n          <jats:title>METHODS<\/jats:title>\n          <jats:p>This retrospective study included patients admitted to the pediatric intensive care unit between December 1, 2019, and November 30, 2020, who received methylnaltrexone for opioid-associated oliguria (spontaneous UOP below 1 mL\/kg\/hr and at least 1 dose of an opioid within the preceding 6 hours).<\/jats:p>\n        <\/jats:sec>\n        <jats:sec>\n          <jats:title>RESULTS<\/jats:title>\n          <jats:p>Twenty-five patients (median age = 5.5 years, IQR 1.7\u201316.4; median weight = 19 kg, IQR 9\u201345) were included. Mean methylnaltrexone dose was 0.15 \u00b1 0.006 mg\/kg. A statistically significant increase in UOP from baseline to 6 hours following methylnaltrexone was observed (p = 0.001), but not all patients responded. Fourteen patients (56%) had no UOP following methylnaltrexone administration, while 11 (44%) demonstrated a robust increase (median = 0 mL\/kg\/hr at baseline [IQR 0\u20130] to 1.96 mL\/kg\/hr [IQR 1.08\u20132.22; p = 0.001]) within 6 hours following methylnaltrexone administration. Younger patients responded better than older patients (responder age = 2.5 years [IQR 0.8\u20137]) versus 11.4 years [IQR 1.75\u201317.5] for non-responders) (p = 0.04). Both intravenous (IV) and subcutaneous (SQ) routes were associated with an increase in UOP (IV, p = 0.04; SQ, p = 0.02). The effect persisted for up to 24 hours after administration. Sixty-four percent of patients required urinary catheter placement. Pain scores (averaged 6 hours before and after methylnaltrexone) remained unchanged (p = 0.44).<\/jats:p>\n        <\/jats:sec>\n        <jats:sec>\n          <jats:title>CONCLUSIONS<\/jats:title>\n          <jats:p>Methylnaltrexone may increase spontaneous UOP in some children with opioid-associated urinary retention, but urinary catheterization rates remain high.<\/jats:p>\n        <\/jats:sec>","DOI":"10.5863\/1551-6776-27.4.373","type":"journal-article","created":{"date-parts":[[2022,5,9]],"date-time":"2022-05-09T19:17:29Z","timestamp":1652123849000},"page":"373-378","source":"Crossref","is-referenced-by-count":4,"title":["Methylnaltrexone in the Management of Opioid-Associated Urinary Retention in Children"],"prefix":"10.5863","volume":"27","author":[{"given":"Skyler B.","family":"Suchovsky","sequence":"first","affiliation":[{"name":"Department of Pharmacy (SBS, HEL), Children's Hospital Colorado, Anschutz Medical Campus, Aurora, CO"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pamela D.","family":"Reiter","sequence":"additional","affiliation":[{"name":"Department of Pharmacy and Division of Pediatric Critical Care (PDR), Children's Hospital Colorado"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hannah E.","family":"Lewis","sequence":"additional","affiliation":[{"name":"Department of Pharmacy (SBS, HEL), Children's Hospital Colorado, Anschutz Medical Campus, Aurora, CO"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy C.","family":"Clevenger","sequence":"additional","affiliation":[{"name":"Clinical Professor, Skaggs School of Pharmacy and Pharmaceutical Sciences (Anschutz Medical Campus), Aurora, CO; Department of Pediatrics and Division of Pediatric Critical Care (ACC), Children's Hospital Colorado and University of Colorado Denver, Anschutz Medical Campus, Aurora, CO."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3883","reference":[{"issue":"3","key":"i2331-348X-27-4-373-b1","series-title":"J Urol","first-page":"918","article-title":"Acute urinary retention in children","volume":"165","year":"2001","unstructured":"Gatti\n              JM,\n            \n            \n              Perez-Brayfield\n              M,\n            \n            \n              Kirsch\n              AJ,\n            \n          \n          .\n\t\t\t\t\tAcute urinary retention in children.\n\t\t\t\t\tJ Urol.\n\t\t\t\t\t2001;\n\t\t\t\t\t165(\n\t\t\t\t\t3):\n\t\t\t\t\t918\u2013\n\t\t\t\t\t921."},{"issue":"5","key":"i2331-348X-27-4-373-b2","series-title":"Drug Safety","first-page":"373","article-title":"Drug-induced urinary retention: incidence, management and prevention","volume":"31","year":"2008","unstructured":"Verhamme\n              KM,\n            \n            \n              Sturkenboom\n              MC,\n            \n            \n              Stricker\n              BH,\n            \n          \n          .\n\t\t\t\t\tDrug-induced urinary retention: incidence, management and prevention.\n\t\t\t\t\tDrug Safety.\n\t\t\t\t\t2008;\n\t\t\t\t\t31(\n\t\t\t\t\t5):\n\t\t\t\t\t373\u2013\n\t\t\t\t\t388."},{"issue":"3","key":"i2331-348X-27-4-373-b3","series-title":"J Pediatr Pharmacol Ther","first-page":"186","article-title":"Patterns of off-label prescribing in the pediatric intensive care unit and prioritizing future research","volume":"20","year":"2015","unstructured":"Czaja\n              AS,\n            \n            \n              Reiter\n              PD,\n            \n            \n              Schultz\n              ML,\n            \n          \n          .\n\t\t\t\t\tPatterns of off-label prescribing in the pediatric intensive care unit and prioritizing future research.\n\t\t\t\t\tJ Pediatr Pharmacol Ther.\n\t\t\t\t\t2015;\n\t\t\t\t\t20(\n\t\t\t\t\t3):\n\t\t\t\t\t186\u2013\n\t\t\t\t\t196."},{"key":"i2331-348X-27-4-373-b4","article-title":"Catheter-associated urinary tract infections (CAUTI). 2017","unstructured":"Centers for Disease Control and Prevention.\n          \n          Catheter-associated urinary tract infections (CAUTI). 2017.\n\t\t\t\t\tAccessed April 5, 2021. https:\/\/www.cdc.gov\/hai\/ca_uti\/uti.html"},{"issue":"7","key":"i2331-348X-27-4-373-b5","series-title":"Ann Intern Med .","first-page":"ITC49","article-title":"Delirium","volume":"173","year":"2020","unstructured":"Mattison\n              MLP.\n            \n          \n          Delirium.\n\t\t\t\t\tAnn Intern Med .2020;\n\t\t\t\t\t173(\n\t\t\t\t\t7):\n\t\t\t\t\tITC49\u2013\n\t\t\t\t\tITC64."},{"issue":"5","key":"i2331-348X-27-4-373-b6","series-title":"Crit Care Med","first-page":"634","article-title":"Physical rehabilitation in critically ill children: a multicenter point prevalence study in the United States","volume":"48","year":"2020","unstructured":"Kudchadkar\n              SR,\n            \n            \n              Nelliot\n              A,\n            \n            \n              Awojoodu\n              R,\n            \n          \n          .\n\t\t\t\t\tPhysical rehabilitation in critically ill children: a multicenter point prevalence study in the United States.\n\t\t\t\t\tCrit Care Med.\n\t\t\t\t\t2020;\n\t\t\t\t\t48(\n\t\t\t\t\t5):\n\t\t\t\t\t634\u2013\n\t\t\t\t\t644."},{"issue":"4","key":"i2331-348X-27-4-373-b7","series-title":"Br J Anaesth","first-page":"565","article-title":"Low-dose naloxone in the treatment of urinary retention during extradural fentanyl causes excessive reversal of analgesia","volume":"80","year":"1998","unstructured":"Wang\n              J,\n            \n            \n              Pennefather\n              S,\n            \n            \n              Russell\n              G.\n            \n          \n          Low-dose naloxone in the treatment of urinary retention during extradural fentanyl causes excessive reversal of analgesia.\n\t\t\t\t\tBr J Anaesth.\n\t\t\t\t\t1998;\n\t\t\t\t\t80(\n\t\t\t\t\t4):\n\t\t\t\t\t565\u2013\n\t\t\t\t\t566."},{"issue":"2","key":"i2331-348X-27-4-373-b8","series-title":"Arch Dis Child Fetal Neonatal Ed","first-page":"F151","article-title":"Reversal of morphine-induced urinary retention after methylnaltrexone","volume":"97","year":"2012","unstructured":"Garten\n              L,\n            \n            \n              Buhrer\n              C.\n            \n          \n          Reversal of morphine-induced urinary retention after methylnaltrexone.\n\t\t\t\t\tArch Dis Child Fetal Neonatal Ed.\n\t\t\t\t\t2012;\n\t\t\t\t\t97(\n\t\t\t\t\t2):\n\t\t\t\t\tF151\u2013\n\t\t\t\t\tF153."},{"issue":"1","key":"i2331-348X-27-4-373-b9","series-title":"Clin Pharmacol Ther","first-page":"48","article-title":"Reversal of opioid-induced bladder dysfunction by intravenous naloxone and methylnaltrexone","volume":"82","year":"2007","unstructured":"Rosow\n              CE,\n            \n            \n              Gomery\n              P,\n            \n            \n              Chen\n              TY,\n            \n          \n          .\n\t\t\t\t\tReversal of opioid-induced bladder dysfunction by intravenous naloxone and methylnaltrexone.\n\t\t\t\t\tClin Pharmacol Ther.\n\t\t\t\t\t2007;\n\t\t\t\t\t82(\n\t\t\t\t\t1):\n\t\t\t\t\t48\u2013\n\t\t\t\t\t53."},{"issue":"4","key":"i2331-348X-27-4-373-b10","series-title":"Pain Pract","first-page":"348","article-title":"The effect of methylnaltrexone on the side effects of intrathecal morphine after orthopedic surgery under spinal anesthesia","volume":"15","year":"2015","unstructured":"Zand\n              F,\n            \n            \n              Amini\n              A,\n            \n            \n              Asadi\n              S,\n            \n          \n          .\n\t\t\t\t\tThe effect of methylnaltrexone on the side effects of intrathecal morphine after orthopedic surgery under spinal anesthesia.\n\t\t\t\t\tPain Pract.\n\t\t\t\t\t2015;\n\t\t\t\t\t15(\n\t\t\t\t\t4):\n\t\t\t\t\t348\u2013\n\t\t\t\t\t354."},{"issue":"5","key":"i2331-348X-27-4-373-b11","series-title":"Pediatr Crit Care Med","first-page":"e240","article-title":"Nalbuphine reduces opioid-associated urinary retention in pediatric patients","volume":"20","year":"2019","unstructured":"Reiter\n              PD,\n            \n            \n              Clevenger\n              AC.\n            \n          \n          Nalbuphine reduces opioid-associated urinary retention in pediatric patients.\n\t\t\t\t\tPediatr Crit Care Med.\n\t\t\t\t\t2019;\n\t\t\t\t\t20(\n\t\t\t\t\t5):\n\t\t\t\t\te240\u2013\n\t\t\t\t\te244."}],"container-title":["The Journal of Pediatric Pharmacology and Therapeutics"],"original-title":[],"link":[{"URL":"https:\/\/jppt.kglmeridian.com\/view\/journals\/jppt\/27\/4\/article-p373.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/meridian.allenpress.com\/jppt\/article-pdf\/27\/4\/373\/3060016\/i2331-348x-27-4-373.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jppt.kglmeridian.com\/downloadpdf\/journals\/jppt\/27\/4\/article-p373.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jppt.kglmeridian.com\/downloadpdf\/journals\/jppt\/27\/4\/article-p373.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T00:34:54Z","timestamp":1747355694000},"score":1,"resource":{"primary":{"URL":"https:\/\/jppt.kglmeridian.com\/view\/journals\/jppt\/27\/4\/article-p373.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"references-count":11,"journal-issue":{"issue":"4"},"URL":"https:\/\/doi.org\/10.5863\/1551-6776-27.4.373","relation":{},"ISSN":["2331-348X","1551-6776"],"issn-type":[{"value":"2331-348X","type":"electronic"},{"value":"1551-6776","type":"print"}],"subject":[],"published":{"date-parts":[[2022]]}}}